Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Elicera Therapeutics: BioStock: Elicera on the positive clinical effect in cancer trial

Elicera Therapeutics

Elicera Therapeutics recently participated at the Oncolytic Virotherapy Summit in Boston, where the immuno-oncology company presented positive data regarding ELC-100. Clinical activity in the form of a reduction in metastases has now been observed in two of the eight patients evaluated so far, providing some support for the candidate's potential in neuroendocrine tumours (NET). BioStock spoke with Elicera's Co-founder Di Yu to learn more about the recently announced results.

Read the full interview with Elicera's Co-founder Di Yu at biostock.se:

https://www.biostock.se/en/2022/12/elicera-on-the-positive-clinical-effect-in-cancer-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.